[Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of Each ClassTicker SymbolName of Exchange on Which Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the Quarterly Period Ended March 31, 2024 Table of Contents Emerging growth company ☐ The Company has an operating lease agreement for its corporate office. The lease includes an option to ...

Catalyst Pharmaceutical (CPRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 8, 2024, might help the stock move higher if these key numbers are better ...

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures:        Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million)        Net result of CHF 54.8 million (2022: CHF -71.1 million)         Cash flow fro ...

Investing in discounted stocks for big gains is a time-tested strategy. Although short-term market fluctuations may capture the attention of many, companies with sustainable growth prospects often prove to be the most lucrative investments over time.Focusing on businesses with competitive advantages, healthy financials and products customers love can position investors to benefit from compounding long-term growth. These companies often have a consistent revenue growth track record and a clear vision for the ...

AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and olderThis follows the first commercial launch of AGAMREE in Germany in January 2024 by SantheraAGAMREE is the first DMD treatment approved across the U.S., EU and UK Pratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in t ...

CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Barclays 26th Annual Global Healthcare Conference being hel ...

Catalyst Pharmaceuticals, Inc. (CPRX) reported adjusted diluted earnings of 53 cents per share for the fourth quarter of 2023, beating the Zacks Consensus Estimate of 48 cents. The company reported adjusted diluted earnings of 31 cents in the year-ago quarter.Total revenues amounted to $110.6 million in the reported quarter, which surpassed the Zacks Consensus Estimate of $106 million. Total product revenues surged 82% from the year-ago quarter’s $60.8 million. The top line primarily comprised product sales ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2023 Earnings Conference Call February 29, 2024 8:30 AM ET Company Participants Michael Kalb - Executive Vice President and Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeffrey Del Carmen - Executive Vice President and Chief Commercial Officer Steven Miller - Executive Vice President, Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical and Regulatory Officer Conference Call Participants Charles Du ...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.42%. A quarter ago, it was expected that this specialty drug company would post a loss of $0.24 per share when it actually produced a loss of $0.24, delivering no surprise.Over the last four quarters, th ...

    Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to Fourth Quarter 2022 Reported 2023 GAAP Net Income of $71.4 Million, $0.63 Per Share Diluted Reported 2023 Non-GAAP Net Income of $223.2 Million, $1.96 Per Share Diluted Bolstered Neuroscience Commercial Portfolio with the FDA Approval of AGAMREE® Commercial Launch of AGAMREE on Track for Q1 2024 Full Year 2024 Total ...